SK Biopharmaceuticals Co., Ltd. (KRX:326030)

South Korea flag South Korea · Delayed Price · Currency is KRW
108,900
+1,900 (1.78%)
At close: Sep 5, 2025
1.78%
Market Cap8.55T
Revenue (ttm)620.28B
Net Income (ttm)255.99B
Shares Out78.31M
EPS (ttm)3,268.81
PE Ratio33.41
Forward PE42.97
Dividendn/a
Ex-Dividend Daten/a
Volume189,020
Average Volume180,323
Open107,400
Previous Close107,000
Day's Range106,400 - 109,500
52-Week Range86,900 - 130,000
Beta0.89
RSI64.72
Earnings DateAug 8, 2025

About SK Biopharmaceuticals

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication, for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, w... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 246
Stock Exchange Korea Stock Exchange
Ticker Symbol 326030
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.